

Harry M. Lander, Ph.D., M.B.A.

Doha, Qatar

+1(917) 696-1991

hazhml@aol.com

Born: August 12, 1965

SUMMARY OF QUALIFICATIONS

- 20 years of professional scientific, business and financial management experience related to biomedical research with increasing responsibility;
- Deeply knowledgeable about operations and research administration
- Team-oriented management style founded on outstanding communication and interpersonal skills
- Excellent public speaker with engaging presentation style
- Highly effective at strategic planning, problem solving and operational excellence

PROFESSIONAL EXPERIENCE

Research Chief – Administration

Sidra Medical and Research Center, Doha, Qatar

2013 – 2015

Sidra Medical and Research Center is a new women's and children's hospital (expected to open in 2018) and was established to provide unparalleled care to Qatari and Middle East residents based on the North American academic medical center model. As part of this model, a research branch was envisioned and I was brought on board to establish the infrastructure.

With an annual research budget of about \$120MM, the research branch was able to hire outstanding scientists and administrative staff to support research focused on the mission of the hospital, particularly around genomics and personalized medicine and cancer immunotherapy.

Reporting directly to the Chief Research Officer, established all of the financial (budgeting, pre- and post-award accounting), operational (HR, procurement, resource allocation, technology transfer) and compliance (IRB, conflicts) infrastructures from scratch. When hired, I was the 4th employee of the research branch and now there are currently 150 employees including scientists and support staff.

In addition to this infrastructure, working with the Chief Research Officer we developed the scientific strategy via a 5-yr Strategic Plan (available on the Sidra website), worked directly with the Ministry of Finance to educate them on the value of science to the country, established an international scientific advisory board and established a national vision to implement research in Qatar (not on the website due to the sensitivity of the document).

Assistant Provost

Weill Cornell Medical College, New York, NY

2012 – 2013

Weill Cornell Medical College (WCMC) has a \$1.4 billion annual budget. The research enterprise comprises of about \$230MM of that activity. There are 1100 full-time faculty of which about 450 are full-time researchers with about 1600 grants and contracts, 1800 IRB protocols and 400 IACUC protocols active.

Reported directly both to the Dean and the Chief Operating Officer, participated in programmatic and operational strategic planning for research. A major part of my work was defining the research programs and faculty that will populate a new \$650MM research building that opened in January 2014. This strategic planning required interaction with WCMC's senior research faculty, development office, and Board of Overseers and a deep understanding of how different research programs can interact synergistically.

Assistant Provost, Research Administration

Weill Cornell Medical College, New York, NY

2009 - 2012

Oversaw 7 direct reports (with a total of about 130 FTE) and 23 core facility directors representing about another 50 FTE. Both of these activities total a budget of \$14MM.

My overarching philosophy is that research administration's clients are the faculty and customer service is key to what this position should focus on by minimizing the administrative burden of the faculty while at the same time protecting the institution. This is a tricky balance that requires an intense focus on communication, empathy and an ability to see the big picture while maintaining an unyielding standard of excellence for staff.

Activities:

- Provide proactive leadership and oversee all aspects of research administration and operations support at Weill Cornell Medical College (WCMC)
 - Develop and oversee short and long term strategies to support and continually improve the research support needs of both basic and clinical investigators at WCMC.
 - Ensure compliance with all policies and guidelines, state and federal regulations, and any other regulatory agency as it relates to the use of radioactive materials.
 - Ensure fiscal policies for research grants, gifts and other funds are adhered to.
 - Develop annual capital and operating budgets and identify other institutional support required for research.
 - Directly manage the Directors responsible for research support operations in the following areas:
 - o Grants and Contracts
 - o IRB/IACUC/IBC
 - o Office of Technology Development
 - o Offices of Environmental Health and Safety and Health Physics
 - o Cores and Services

o Animal Resource Facility

- Assess the efficiency and effectiveness of the research administration and operations infrastructure at WMC. Where necessary, improve and enhance the functions such that the scientists and investigators are supported in their discovery efforts.
- Assist Executive Vice Dean and Associate Provost with preparation for Board of Overseer and Trustee meetings.
- Coordinate and integrate research administration efforts with other areas (e.g., Patent Counsel, Information Systems, Compliance, Departments).
- Provide oversight for clinical trials administration and operations that support all clinical trials (e.g., patient enrollment and registration, clinical investigation policy and oversight, quality assurance, education, etc.)
- Support the planning and evaluation of new efforts such as a cancer center initiative and the clinical and translational science award.
- Manage and monitor the financial and operational performance of all core facilities and shared resources.
- Spearhead efforts to computerize research administration and support.
- Work with faculty to identify operational areas that impact recruitment and retention.
- Evaluate all operational areas for service-orientation and implement structural, personnel and/or business process changes.

Major Accomplishments

- Taken paper-based pre-award research administrative business processes and moved them into electronic-based. I have taken our Medical College from completely paper-based to implementing electronic systems for IRB submission, IACUC submission, internal routing (internal compliance form for each grant), conflict of interest, time and effort, core facility laboratory information management system for automated billing and electronic service request. This has required frequent interaction and feedback from faculty. Additionally, it has required an ability to work with the CIO and various IT staff as well as all departmental administrators. The goal of this is to minimize the administrative burden on faculty while maintaining compliance.
- Converted the grants and contracts office as well as the IRB office from a first-in first-out process to a departmental-based process. By assigning specific grants- or IRB-specialists to departments, the faculty are able to establish relationships with the staff in these offices and this leads to much better customer service.
- Established space-usage metrics and faculty productivity reports for Dean to help him in decision-making.

Assistant Research Professor
Department of Pharmacology
Weill Cornell Medical College, New York, NY

2009 - 2013

Associate Dean for Research Administration
2009

2004 -

Weill Cornell Medical College, New York, NY

- Worked with WCMC-Qatar to establish their research administrative infrastructure – this required multiple trips to Doha and working with WCMC-Qatar administration
- Worked with The Methodist Hospital Research Institute (Houston, Texas) to establish their research administrative infrastructure
- Established trans-institutional research programs between WCMC and Cornell University (Ithaca), WCMC and The Methodist Hospital Research Institute, and WCMC and WCMC-Qatar

Assistant Dean for Research Administration 2003 – 2004
Weill Cornell Medical College, New York, NY

Assistant Professor 1995 - 2000
Program in Biochemistry and Structural Biology
Cornell University Graduate School of Medical Sciences

Postdoctoral Research Associate 1993 - 1995
Department of Biochemistry
Cornell University Medical College, New York, NY

Postdoctoral Research Associate 1992 – 1993
Department of Biochemistry
Cornell University Medical College, New York, N.Y.
(Sponsor: Abraham Novogrodsky, M.D., Ph.D.)

NON-ACADEMIC EMPLOYMENT

President and Owner 2002 - 2003
The Gramercy Group, LLC, New York, NY

Managing Director, Equities Trading 2001 - 2002
The Lancer Group, New York, NY

Securities Trader 1999 - 2001
Aegis Capital, Valley Stream NY

EDUCATION

M.B.A., Finance, 2001
The Stern School of Business, New York, University, New York, NY

Ph.D., Biochemistry, 1992
Cornell University Graduate School of Medical Sciences, New York, NY

B.S., Biochemistry and B.S., Chemistry, 1987

State University of New York at Stony Brook, Stony Brook, NY

HONORS AND AWARDS

NIH Postdoctoral Traineeship HL07423	1993-1994
Norman and Rosita Winston Foundation Fellowship	1994-1995
R29 FIRST Award 1R29HL37637, Principal Investigator	1995-2000
R01HL34215, Co-Investigator	1996-2001
R01GM55509, Principal Investigator	1997-2001
Pew Scholar Nominee of Cornell University	1997
NIH Study Section - Special Emphasis Panel	1997
NIH Presidential Early Career Award Nominee	1997
Editorial Board: Antioxidants and Redox Signaling	1999

MEMBERSHIPS

American Society of Biochemistry and Molecular Biology
American Association of Immunologists
New York Academy of Sciences

PEER REVIEW

Nature
Proceedings of the National Academy of Sciences USA
Journal of Experimental Medicine
Journal of Immunology
Journal of Pharmacology and Experimental Therapeutics
Journal of Cellular Physiology
Biochemica et Biophysica Acta
International Journal of Cancer
Circulation
USDA National Research Initiative Competitive Grants Program

INVITED LECTURES

1995 New York Academy of Sciences, New York, N.Y. "Nitric Oxide Signaling Through p21^{ras}".
1995 Hunter College, New York, N.Y. "p21^{ras} and Nitric Oxide Signaling"
1996 Bar Ilan University, Tel Aviv, Israel "Redox Regulation of T Cell Function"

- 1997 University of Rochester Medical Center, Rochester, NY, "Triggering of Ras Signal Transduction by Nitric Oxide".
- 1997 University of Pennsylvania, Philadelphia, PA, "Ras as a Redox Target".
- 1997 Texas University A&M, College Station, TX, "Redox Signaling".

GRANT SUPPORT

NIH PHS R01-GM55509

Title: Redox Regulation of T Cell Function

Principal Investigator: Harry M. Lander Effort: 25%

Period of Support: 7/1/97 - 6/31/01

Direct Costs: 159,571/year Total Direct Costs: \$523,166

NIH PHS 1R29-HL37637

Title: Nitric Oxide-G Protein Signaling in Pathophysiology

Principal Investigator: Harry M. Lander Effort: 50%

Period of Support: 4/1/95 - 3/31/00

Direct Costs: \$62,100/year Total Direct Costs: \$344,874

NIH PHS R01-HL34215

Title: Cardiac Anaphylaxis

Principal Investigator: Roberto Levi

Role on Grant: Co-Investigator Effort: 10%

Period of Support: 4/1/96 - 3/31/01

Direct Costs: \$10,000/year (salary)

NIH PHS 5P01-HL46403

Title: Vascular Cell Regulation and Atherogenesis

Principal Investigator: David Hajjar

Role on Grant: Co-Investigator, Project 6, Effort: 10%

Period of Support: 8/1/96 - 7/30/01

Direct Costs: \$25,000/year (technical support)

The Schiffman Foundation

Principal Investigator: Harry M. Lander

Period of Support: 7/95 - 6/96

Amount of Support: \$10,000/year

NIH PHS HL-07423

Postdoctoral Traineeship

Period of Support: 7/1/93 - 6/30/94

Amount of Support: \$19,000/year

Norman and Rosita Winston Foundation Fellowship

Principal Investigator: Harry M. Lander

Period of Support: 7/1/94 - 6/30/95

Amount of Support: \$25,000/year

Nina W. Werblow Charitable Trusts
Principal Investigator: Harry M. Lander
Period of Support: 11/95 - 10/96
Amount of Support: \$9,000/year

TEACHING EXPERIENCE

1996-2000 Molecules to Cells (first year medical school course) - Group leader
1997 Cell Structure and Function (first year graduate school course) - Section head and
lecturer on protein structure and function.
1995-1997 Biochemistry and Structural Biology Journal Club (first and second year graduate
students) - Co-course director.
1994-1996 Medical School Biochemistry Course (first year course) - Discussion group leader.
1994-1996 Graduate School Biochemistry Course (first year course) - Course lecturer on
carbohydrate metabolism and metabolic regulation.

INTRAMURAL COMMITTEES

1996-2000 Graduate School Alumni Committee
1995-1997 Admissions Committee, Program in Biochemistry and Structural Biology
1996 Vincent du Vigneaud Evaluation Committee

Publications

1. **Lander, H. M.**, Levine, D. M., and Novogrodsky, A. 1992. Hemin Stimulation of cAMP Production in Human Lymphocytes. FEBS Lett. 303:242-246.
2. **Lander, H. M.**, Levine D. M., and Novogrodsky, A. 1992. Agonistic Effects of Tyrphostins on Human Peripheral Blood Mononuclear Cells. Cell. Immunol. 144:155-168.
3. Moskal, J. R., Sinnott M., Kornblith, P. L., LaSala, P., Levine, D. M., Parker, T. S., and **Lander, H. M.** 1992. The effect of lipoproteins on human glioblastoma growth in vitro. Mol. Chem. Neuropath. 17:169-181.
4. **Lander, H. M.**, Levine D. M., and Novogrodsky, A. 1992. Stress Stimuli-Induced Lymphocyte Activation. Cell. Immunol. 145:146-155.
5. **Lander, H. M.**, Sehajpal, P., Levine, D.M., and Novogrodsky, A. 1993. Activation of Human Peripheral Blood Mononuclear Cells by Nitric Oxide Generating Compounds. J. Immunol. 150:1509-1516.
6. **Lander, H. M.**, Levine D. M., and Novogrodsky, A. 1993. Hemin Enhancement of Glucose Transport in Human Lymphocytes: Stimulation of Protein Tyrosine Phosphatase and Activation of p56^{lck} Tyrosine Kinase. Biochem. J. 291:281-297.

7. Patya, M., **Lander, H. M.**, and Novogrodsky, A. 1993. Hemin-Induced Cap Formation in Lymphocytes: Inhibition by Protein Tyrosine Kinase Inhibitors. Exp. Cell Res. 205:159-164.
8. **Lander, H. M.**, Sehajpal, P. K., and Novogrodsky, A. 1993. Nitric Oxide Signaling: A Possible Role For G Proteins. J. Immunol. 151:7182-7187.
9. Ding, A., Hwang, S., **Lander, H. M.**, and Xie, Q. 1995. Macrophages Derived from C3H/HeJ (LPS^d) Mice Respond to Bacterial Lipopolysaccharide by Activating NF- κ B. J. Leukocyte Biol. 57:174-179.
10. **Lander, H. M.**, Ogiste, J. S., Pearce, S. F. A., Levi, R., and Novogrodsky, A. 1995. Nitric Oxide-Stimulated Guanine Nucleotide Exchange on p21^{ras}. J. Biol. Chem. 270:7017-7020.
11. Hajjar, D. P., **Lander, H. M.**, Pearce, S. F. A., and Pomerantz, K. B. 1995. Nitric Oxide Enhances Prostaglandin-H Synthase-1 Activity by a Heme-Independent Mechanism: Evidence Implicating Nitrosothiols. J. Am. Chem. Soc. 117, 3340-3346.
12. Mirza, U. A., Chait, B. T. and **Lander, H. M.** 1995. Monitoring Reactions of Nitric Oxide with Peptides and Proteins by Electrospray Ionization-Mass Spectrometry. J. Biol. Chem. 270, 17185-17188.
13. **Lander, H. M.**, Ogiste, J. S., Teng, K. K., and Novogrodsky, A. 1995. p21^{ras} as a Common Signaling Target of Reactive Free Radicals and Cellular Redox Stress. J. Biol. Chem. 270:21195-21198.
14. Imamura, M., Seyedi, N., **Lander, H. M.**, and Levi, R. 1995. Functional Identification of Histamine H₃ Receptors in the Human Heart. Circ. Res. 77, 206-210.
15. Teng, K. K., **Lander, H. M.**, Fajardo, E., Mahadeo, D. K., Hempstead, B. L., and Birge, R. B. 1995. v-Crk modulation of growth factor-induced PC12 cell differentiation involves the Src Homology Domain 2 of v-Crk and sustained activation of the Ras/mitogen-activated protein kinase pathway. J. Biol. Chem. 270:20677-20681.
16. Imamura, M., **Lander, H. M.**, and Levi, R. 1996. Activation of Histamine H₃-Receptors Inhibits Carrier-Mediated Norepinephrine Release During Prolonged Myocardial Ischemia: Comparison with Adenosine-A₁ and Adrenergic- α ₂ Receptors. Circ. Res. 78:475-481.
17. Levi, R., Park, K. H., Imamura, M., Seyedi, N., and **Lander, H. M.** 1995. Nitric Oxide and Peripheral Adrenergic Neuromodulation. Adv. in Pharmacol. 34:399-413.
18. **Lander, H. M.**, Milbank, A. J., Tauras, J. M., Hajjar, D. P., Hempstead, B. L., Schwartz, G. D., Kraemer, R. T., Mirza, U. A., Chait, B. T., Campbell-Burk, S., and Quilliam, L. A. 1996. Redox Regulation of Cell Signalling. Nature 381:380-381.
19. **Lander, H. M.**, Jacovina, A. T., Davis, R. J., and Tauras, J. M. 1996. Differential Activation of MAP Kinases by Nitric Oxide-Related Species. J. Biol. Chem. 271:19705-1970.
20. **Lander, H. M.** 1996. Nitric Oxide as an Immune Signaling Molecule. Methods: A Companion to Methods in Enzymology. 10:15-20.
21. **Lander, H. M.** 1997. An Essential Role for Free Radicals and Related Species in Signal

Transduction. FASEB J. 11;118-124.

22. **Lander, H. M.**, Hajjar, D. P., Hempstead, B. L., Mirza, U. A., Chait, B. T., Campbell, S., and Quilliam, L. A. 1997. A Molecular Redox Switch on p21^{ras}: Structural Basis for the Nitric Oxide-p21^{ras} Interaction. J. Biol. Chem. 272;4323-4326.

23. **Lander, H. M.**, Ogiste, J. S., Tauras, J. M., Hori, O., Moss, R. A., and Schmidt, A.-M. 1997. Activation of the Receptor for Advanced Glycation End Products Triggers a p21^{ras}-Dependent MAP Kinase Pathway Regulated by Oxidant Stress. J. Biol. Chem. 272;17810-17814.

24. Seyedi, N., Win, T., **Lander, H. M.**, and Levi, R. 1997. Bradykinin B₂-Receptor Activation Augments Norepinephrine Exocytosis from Cardiac Sympathetic Nerve Endings: Mediation by Autocrine/Paracrine Mechanisms. Circ. Res. 81;774-784.

25. Pomerantz, K. B., **Lander, H. M.**, Summers, B., Robishaw, J. D., Balcueva, E., and Hajjar, D. P. 1997. G Protein-Mediated Signaling in Cholesterol-Enriched Arterial Smooth Muscle Cells: I. Reduced Membrane-Associated G Protein content Due to Diminished Isoprenylation of G_γ Subunits and p21^{ras}. Biochemistry 36;9523-9531.

26. Pomerantz, K. B., **Lander, H. M.**, Summers, B., and Hajjar, D. P. 1997. G Protein-Mediated Signaling in Cholesterol-Enriched Arterial Smooth Muscle Cells: II. Role of Protein Kinase C δ in the Regulation of Eicosanoid Production. Biochemistry 36;9532-9539.

27. Deora, A. A., Win, T., Vanhaesebroeck, B. and **Lander, H. M.** 1998. A Redox-Triggered Ras-Effector Interaction: Recruitment of Phosphatidylinositol 3-kinase to Ras by Redox Stress. J. Biol. Chem. 273;29923-29928.

28. Basu, A., Sehajpal, P. K., Ogiste, J. S. and **Lander, H. M.** 1999. Targeting Cysteine Residues of Human Immunodeficiency Virus Type 1 Protease by Reactive Free Radical Species. Antiox. and Redox Signaling 1;105-112.

29. Sehajpal, P. K., Basu, A., Ogiste, J. S. and **Lander, H. M.** 1999. Reversible S-Nitrosation and Inhibition of HIV-1 Protease. Biochemistry 38;13407-13413.

30. Teng, K. K., Esposito, D. K., Schwartz, G. D., **Lander, H. M.** and Hempstead, B. L. 1999. Activation of C-Ha-Ras by Nitric Oxide Modulates Survival Responsiveness in Neuronal PC12 Cells. J. Biol. Chem. 274;37315-37320.

31. Deora, A. A., Hajjar, D. P. and **Lander, H. M.** 2000. Recruitment and Activation of RAF-1 Kinase by Nitric Oxide-Activated Ras. Biochemistry 39;9901-9908.

32. Sehajpal P. K., **Lander H. M.** 2000. Identifying and Counting Protein Modifications Triggered by Nitrosative Stress. Methods in Molecular Biology 99;3-14.

33. Kovjazin, R., Eldar, T., Patya, M., Vanichkin, A., **Lander, H. M.** and Novogrodsky, A. 2003. Ferrocene-Induced Lymphocyte Activation and Anti-Tumor Activity is Mediated by Redox-Sensitive Signaling. FASEB Journal 17;467-469.

34. Patya, M., Zahalka, M. A., Vanichkin, A., Rabinokov, A., Miron, T., Mirelman, D., Wilchek, M., **Lander, H. M.** and Novogrodsky, A. 2004. Allicin Stimulates Lymphocytes and Elicits an Antitumor Effect: a Possible Role of p21^{ras}. International Immunology 16;275-281.

35. Sredni, B., Gal, R., Cohen, I. J., Dazard, J. E., Givol, D., Gafter, U., Motro, B., Eliyahu, S., Albeck, M., **Lander, H. M.**, Kalechman, Y. 2004. Hair Growth Induction by the Tellurium Immunomodulator AS101: Association with Delayed Terminal Differentiation of Follicular Keratinocytes and Ras-Dependent Up-Regulation of KGF Expression. FASEB J. 18;400-402.
36. Mittar, D., Sehajpal, P. K., **Lander, H. M.** 2004. Nitric Oxide Activates Rap1 and Ral in a Ras-Independent Manner. Biochem. Biophys. Res. Commun. 322;203-209.

Book Chapters

1. Levi R., Park, K. H., Imamura, M., Seyedi, S., Omoniyi, A. T., and **Lander H. M.** (1995) Nitric Oxide and Peripheral Adrenergic Neuromodulation, in: *Nitric Oxide: Biochemistry, Molecular Biology, and Therapeutic Implications*, ed. L. Ignarro and F. Murad, Academic Press, Inc.
2. **Lander H. M.** (1998) Identifying and Counting Protein Modifications Triggered by Nitrosative Stress, in: *Methods in Molecular Biology*, ed. S. Keyse, Humana Press, Inc.
3. Deora A. M., and **Lander H. M.** (1998) Regulation of Signal Transduction and Gene Expression by Reactive Nitrogen Species, in: *Antioxidant and Redox Regulation of Genes*, eds. C. K. Sen, H. Sies and P. A. Baeuerle, Academic Press, Inc.
4. Deora A. M., and **Lander H. M.** (1998) Regulation of Gene Expression by Nitric Oxide, in: *Nitric Oxide and the Cardiovascular System*, eds. J. Loscalzo and J. A. Vita, Humana Press, Inc